Official UK procurement notice
EYLEA 3.6MG/90MICROLITRE SOLUTION FOR INJECTION
Authority: Western Health and Social Care Trust (NHS & healthcare)
What is being bought
Published requirement descriptionSupply of Eylea Brand of AFLIBERCEPT 40 mg/ml solution for injection in pre-filled syringe to meet clinical need in the Western Trust until 30/04/2027.
Open work like this
This notice no longer takes bids · live search, filters set
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Bayer PlcAFLIBERCEPT 40 mg/ml solution for injection in pre-filled syringe10 Nov 2026 – 30 Apr 2027 | £175,268 | 27 Oct 2026 | Awarded |
Contracts
AFLIBERCEPT 40 mg/ml solution for injection in pre-filled syringe · Bayer Plc
- Signed
- 27 Oct 2026
- Value
- £175,268
- Period
- 10 Nov 2026 – 30 Apr 2027
- Status
- active
No agreed KPIs: KPIs have not been set as this is a temporary arrangement to maintain continuity of patient care and medicine supply whilst clinical assessment of an alternative contracted product is completed. Contract performance will be monitored through routine supplier performance and supply assurance processes.
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 28 Oct 2026, 17:20 GMT
- Last source update
- 10 Nov 2026, 10:06 GMT
- Authority reference
WT-PHARM-2026-09- FTS notice number
2026/S 000-106519- Latest notice
- Contract details notice (UK7)
- Delivery area
- Official registry OCID
ocds-h6vhtk-0792e0Find a Tender
- Why no open competition
- Single Suppliers Technical Reasons
- Published justification
Continuity of patient care is required whilst clinicians complete assessment of the potential introduction of the contracted aflibercept biosimilar comparator. Established patients are currently treated with Eylea under existing treatment regimens. Continued supply of Eylea is required pending completion of clinical review, approval of any switching strategy, and implementation decisions.
How it was run
Official notice- Submission deadline
- —
Timeline
6 Nov 2026 → 10 Nov 2026 · 2 dates- Standstill ends7 days ago6 Nov 2026, 23:59 GMT
- Notice published3 days ago10 Nov 2026, 10:06 GMT
Notice history
4 events · 3 releases on Find a Tender · since 28 Oct 2026- Transparency notice published28 Oct 2026, 17:20 GMTUK5
- Contract award notice published28 Oct 2026, 17:56 GMTUK6
- Contract details notice published10 Nov 2026, 10:06 GMTUK7
- Contract signature expected10 Nov 2026, 23:59 GMTscheduled
Contracting authority & participating public bodies
Bidders & participating suppliers
1 commercial party on the notice- BAYER PUBLIC LIMITED COMPANYAwarded supplier
Official documents & specifications (3)
Official links; attachments are not copiedNotices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Transparency notice Transparency notice on Find a Tender